What are the side effects of IGF-1 LR3?

What side effects are documented for IGF-1 LR3?

No controlled human study of IGF-1 LR3 side effects was found in the sources checked. A 2026 review by Dominikowski and colleagues describes reports of hypoglycaemia symptoms, meaning signs of low blood sugar, from use outside medical care. It warns that many of these reports do not come from clinics or studies. The review calls cancer concerns theoretical and notes there are no long-term safety data. A personal story cannot show how often a problem happens. Neither can a theory about how the molecule works. Nor can either show that IGF-1 LR3 caused it. So a human safety profile is not established.

The review placed IGF-1 LR3 in its lowest evidence group, with no peer-reviewed human studies. It said contact with compounds like this should be treated as poorly supported by evidence. A report that someone felt unwell is an account, not a controlled finding. Only a controlled study, where a comparison group is followed in the same way, could show whether the analogue caused it.

What studies show about IGF-1 LR3 lists the cell and animal research that does exist.

What does the label of the approved IGF-1 medicine warn about?

The FDA label for mecasermin (Increlex) lists these warnings: severe low blood sugar with seizures, serious allergic reactions, and raised pressure inside the skull. It also lists enlarged lymphoid tissue, which is part of the immune system, and slipped capital femoral epiphysis, a hip problem where the top of the thigh bone slips. Scoliosis getting worse and malignant tumours are listed too. The label covers growth failure in children aged two and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion and antibodies that block growth hormone. These warnings are about mecasermin, a different molecule. They are not measured side effects of IGF-1 LR3.

Mecasermin has the same sequence as human IGF-1, and IGF-1 LR3 does not. The label gives no safety data for IGF-1 LR3. It describes children treated for a defined condition, not other groups. These records do not show whether IGF-1 LR3 shares those effects in people.

The label does show why researchers watch blood sugar. It says the medicine lowers blood sugar the way insulin does. The label is dated July 2025. The general peptide side-effects guide explains how to read labels like this.

What did animal studies note about IGF-1 LR3?

Animal studies noted changes in hormones and body measures, not human side effects. In guinea pigs given a 7-day infusion of LR3-IGF-I, blood levels of IGF-I, IGF-II and IGF binding proteins went down. At the same time, several organs grew heavier compared with body weight. In normal fetal sheep, a 1-week infusion lowered insulin and lowered the release of insulin in response to sugar. In fetal sheep that were growing too slowly, the infusion was followed by lower amino acids in the blood. These results come from a 1995 guinea pig study and a 2025 sheep study.

These observations come from different species and settings. Fetal sheep model a pregnancy, not an adult person. The studies show that the analogue changes other hormone systems in animals. They are not reports of harm in people, and no human equivalent was measured.

Evidence limits

Can the contents of an IGF-1 LR3 product be trusted?

The 2026 review also gives uncertainty about what is in products from unregulated supply chains as a reason for caution. The TGA, Australia's medicines regulator, states that unapproved peptide products have not been assessed by the TGA for safety, quality or effectiveness (TGA advisory, 13 April 2026). That advisory names other compounds as examples and does not name IGF-1 LR3.

The peptide quality and verification hub explains how a certificate of analysis and a mass spectrometry result describe what a vial contains. How mass spectrometry confirms peptide identity explains the test used in this case.